Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Hematopoietic stem cell transplantation in primary central nervous system lymphoma: a review of the literature.

Gaut D, Schiller GJ.

Int J Hematol. 2019 Jan 22. doi: 10.1007/s12185-019-02594-1. [Epub ahead of print] Review.

PMID:
30671909
2.

High-Dose Vincristine Sulfate Liposome Injection, for Advanced, Relapsed, or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in an Adolescent and Young Adult Subgroup of a Phase 2 Clinical Trial.

Schiller GJ, Damon LE, Coutre SE, Hsu P, Bhat G, Douer D.

J Adolesc Young Adult Oncol. 2018 Oct;7(5):546-552. doi: 10.1089/jayao.2018.0041. Epub 2018 Sep 21.

PMID:
30239252
3.

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.

Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC.

J Clin Oncol. 2018 Sep 10;36(26):2684-2692. doi: 10.1200/JCO.2017.77.6112. Epub 2018 Jul 19.

4.

Response.

Molina A, Winston DJ, Pan D, Schiller GJ.

Biol Blood Marrow Transplant. 2018 Sep;24(9):1953-1954. doi: 10.1016/j.bbmt.2018.06.012. Epub 2018 Jul 17. No abstract available.

PMID:
29909155
5.

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML.

Cortes JE, Tallman MS, Schiller GJ, Trone D, Gammon G, Goldberg SL, Perl AE, Marie JP, Martinelli G, Kantarjian HM, Levis MJ.

Blood. 2018 Aug 9;132(6):598-607. doi: 10.1182/blood-2018-01-821629. Epub 2018 Jun 6.

6.

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.

Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Pigneux A, Horst HA, Récher C, Klimek VM, Cortes JE, Carella AM, Egyed M, Krug U, Fox JA, Craig AR, Ward R, Smith JA, Acton G, Kantarjian HM, Stuart RK.

Haematologica. 2018 Nov;103(11):e514-e518. doi: 10.3324/haematol.2018.191361. Epub 2018 May 24. No abstract available.

7.

Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia.

Thompson AA, Walters MC, Kwiatkowski J, Rasko JEJ, Ribeil JA, Hongeng S, Magrin E, Schiller GJ, Payen E, Semeraro M, Moshous D, Lefrere F, Puy H, Bourget P, Magnani A, Caccavelli L, Diana JS, Suarez F, Monpoux F, Brousse V, Poirot C, Brouzes C, Meritet JF, Pondarré C, Beuzard Y, Chrétien S, Lefebvre T, Teachey DT, Anurathapan U, Ho PJ, von Kalle C, Kletzel M, Vichinsky E, Soni S, Veres G, Negre O, Ross RW, Davidson D, Petrusich A, Sandler L, Asmal M, Hermine O, De Montalembert M, Hacein-Bey-Abina S, Blanche S, Leboulch P, Cavazzana M.

N Engl J Med. 2018 Apr 19;378(16):1479-1493. doi: 10.1056/NEJMoa1705342.

8.

Increased Incidence of Nocardial Infections in an Era of Atovaquone Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients.

Molina A, Winston DJ, Pan D, Schiller GJ.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1715-1720. doi: 10.1016/j.bbmt.2018.03.010. Epub 2018 Mar 16.

PMID:
29555315
9.

Closing the gap: Novel therapies in treating acute lymphoblastic leukemia in adolescents and young adults.

Friend BD, Schiller GJ.

Blood Rev. 2018 Mar;32(2):122-129. doi: 10.1016/j.blre.2017.09.005. Epub 2017 Sep 21. Review.

PMID:
28969872
10.

A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia.

Reed GA, Schiller GJ, Kambhampati S, Tallman MS, Douer D, Minden MD, Yee KW, Gupta V, Brandwein J, Jitkova Y, Gronda M, Hurren R, Shamas-Din A, Schuh AC, Schimmer AD.

Cancer Med. 2016 Nov;5(11):3031-3040. doi: 10.1002/cam4.845. Epub 2016 Oct 13.

11.

Acute Myeloid Leukemia: How Do We Measure Success?

Sasine JP, Schiller GJ.

Curr Hematol Malig Rep. 2016 Dec;11(6):528-536. doi: 10.1007/s11899-016-0346-x. Review.

PMID:
27604228
12.

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD-Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation.

Schiller GJ, Tuttle P, Desai P.

Biol Blood Marrow Transplant. 2016 Jun;22(6):982-990. doi: 10.1016/j.bbmt.2016.01.013. Epub 2016 Jan 16. Review.

13.

High-Intensity Induction in the Elderly.

Schiller GJ.

Acta Haematol. 2016;135(1):53-4. doi: 10.1159/000438481. Epub 2015 Oct 8. No abstract available.

PMID:
26444244
14.

Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation.

Uy GL, Costa LJ, Hari PN, Zhang MJ, Huang JX, Anderson KC, Bredeson CN, Callander NS, Cornell RF, Perez MA, Dispenzieri A, Freytes CO, Gale RP, Garfall A, Gertz MA, Gibson J, Hamadani M, Lazarus HM, Kalaycio ME, Kamble RT, Kharfan-Dabaja MA, Krishnan AY, Kumar SK, Kyle RA, Landau HJ, Lee CH, Maiolino A, Marks DI, Mark TM, Munker R, Nishihori T, Olsson RF, Ramanathan M, Rodriguez TE, Saad AA, Savani BN, Schiller GJ, Schouten HC, Schriber JR, Scott E, Seo S, Sharma M, Ganguly S, Stadtmauer EA, Tay J, To LB, Vesole DH, Vogl DT, Wagner JL, Wirk B, Wood WA, D'Souza A.

Bone Marrow Transplant. 2015 Dec;50(12):1513-8. doi: 10.1038/bmt.2015.190. Epub 2015 Aug 24.

15.

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.

Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, Roboz GJ, Odenike O, Thomas X, Havelange V, Maertens J, Derigs HG, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK, Kantarjian HM.

Lancet Oncol. 2015 Sep;16(9):1025-1036. doi: 10.1016/S1470-2045(15)00201-6. Epub 2015 Jul 30.

16.

New cancers after autotransplantations for multiple myeloma.

Mahindra A, Raval G, Mehta P, Brazauskas R, Zhang MJ, Zhong X, Bird JM, Freytes CO, Hale GA, Herzig R, Holmberg LA, Kamble RT, Kumar S, Lazarus HM, Majhail NS, Marks DI, Moreb JS, Olsson R, Saber W, Savani BN, Schiller GJ, Tay J, Vogl DT, Waller EK, Wiernik PH, Wirk B, Lonial S, Krishnan AY, Dispenzieri A, Brandenburg NA, Gale RP, Hari PN.

Biol Blood Marrow Transplant. 2015 Apr;21(4):738-45. doi: 10.1016/j.bbmt.2014.12.028. Epub 2014 Dec 31.

17.

Emerging strategies for high-risk and relapsed/refractory acute myeloid leukemia: novel agents and approaches currently in clinical trials.

Sasine JP, Schiller GJ.

Blood Rev. 2015 Jan;29(1):1-9. doi: 10.1016/j.blre.2014.07.002. Epub 2014 Jul 16. Review.

PMID:
25441922
18.

An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes.

Goldberg SL, Fenaux P, Craig MD, Gyan E, Lister J, Kassis J, Pigneux A, Schiller GJ, Jung J, Jane Leonard E, Fingert H, Westervelt P.

Leuk Res Rep. 2014 Jul 5;3(2):58-61. doi: 10.1016/j.lrr.2014.06.003. eCollection 2014.

19.

Allogeneic transplantation as therapy for acute myelogenous leukemia in the elderly.

Schiller GJ.

Biol Blood Marrow Transplant. 2014 Apr;20(4):437-8. doi: 10.1016/j.bbmt.2014.01.024. Epub 2014 Jan 29. No abstract available.

20.

Evolving treatment strategies in patients with high-risk acute myeloid leukemia.

Schiller GJ.

Leuk Lymphoma. 2014 Nov;55(11):2438-48. doi: 10.3109/10428194.2014.881479. Epub 2014 Mar 7. Review.

PMID:
24432896
21.

High-risk acute myelogenous leukemia: treatment today ... and tomorrow.

Schiller GJ.

Hematology Am Soc Hematol Educ Program. 2013;2013:201-8. doi: 10.1182/asheducation-2013.1.201. Review.

PMID:
24319182
22.

Myelodysplasia.

Schiller GJ, Reese N.

Hematology. 2013 Sep;18(5):307-8. doi: 10.1179/1024533213Z.000000000221. No abstract available.

PMID:
24020490
23.

High-dose cytarabine (HD araC) in the treatment of leukemias: a review.

Reese ND, Schiller GJ.

Curr Hematol Malig Rep. 2013 Jun;8(2):141-8. doi: 10.1007/s11899-013-0156-3. Review.

PMID:
23666364
24.

Salvage second hematopoietic cell transplantation in myeloma.

Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, Kumar S, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Nishihori T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobadi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA, Landau H, Schouten HC, Maziarz RT, Mikhael J, Kindwall-Keller T, Stiff PJ, Gibson J, Lonial S, Krishnan A, Dispenzieri A, Hari P; Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research.

Biol Blood Marrow Transplant. 2013 May;19(5):760-6. doi: 10.1016/j.bbmt.2013.01.004. Epub 2013 Jan 5.

25.

Secondary hemophagocytic lymphohistiocytosis in adults: an update on diagnosis and therapy.

Kleynberg RL, Schiller GJ.

Clin Adv Hematol Oncol. 2012 Nov;10(11):726-32. Review.

PMID:
23271259
26.

Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma.

Weber DM, Graef T, Hussein M, Sobecks RM, Schiller GJ, Lupinacci L, Hardwick JS, Jagannath S.

Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):319-24. doi: 10.1016/j.clml.2012.07.007.

PMID:
23040438
27.

Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research.

Keating A, DaSilva G, Pérez WS, Gupta V, Cutler CS, Ballen KK, Cairo MS, Camitta BM, Champlin RE, Gajewski JL, Lazarus HM, Lill M, Marks DI, Nabhan C, Schiller GJ, Socie G, Szer J, Tallman MS, Weisdorf DJ.

Haematologica. 2013 Feb;98(2):185-92. doi: 10.3324/haematol.2012.062059. Epub 2012 Sep 14.

28.
29.

When a gold standard is made of tin.

Schiller GJ.

Blood. 2010 Nov 25;116(22):4386-7. doi: 10.1182/blood-2010-08-300566. No abstract available.

30.

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ, Klimek VM, Nimer SD, Gilliland DG, Dutreix C, Huntsman-Labed A, Virkus J, Giles FJ.

J Clin Oncol. 2010 Oct 1;28(28):4339-45. doi: 10.1200/JCO.2010.28.9678. Epub 2010 Aug 23.

31.

Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.

Cortes J, Moore JO, Maziarz RT, Wetzler M, Craig M, Matous J, Luger S, Dey BR, Schiller GJ, Pham D, Abboud CN, Krishnamurthy M, Brown A Jr, Laadem A, Seiter K.

J Clin Oncol. 2010 Sep 20;28(27):4207-13. doi: 10.1200/JCO.2009.26.8896. Epub 2010 Aug 16.

32.

Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients.

Winston DJ, Bartoni K, Territo MC, Schiller GJ.

Biol Blood Marrow Transplant. 2011 Apr;17(4):507-15. doi: 10.1016/j.bbmt.2010.04.017. Epub 2010 May 9.

33.

CMV central nervous system disease in stem-cell transplant recipients: an increasing complication of drug-resistant CMV infection and protracted immunodeficiency.

Reddy SM, Winston DJ, Territo MC, Schiller GJ.

Bone Marrow Transplant. 2010 Jun;45(6):979-84. doi: 10.1038/bmt.2010.35. Epub 2010 Mar 1. Review.

PMID:
20190836
34.

Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.

Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF.

J Clin Oncol. 2010 Feb 1;28(4):556-61. doi: 10.1200/JCO.2009.23.9178. Epub 2009 Dec 21.

PMID:
20026803
35.

Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia.

Schiller GJ, O'Brien SM, Pigneux A, Deangelo DJ, Vey N, Kell J, Solomon S, Stuart RK, Karsten V, Cahill AL, Albitar MX, Giles FJ.

J Clin Oncol. 2010 Feb 10;28(5):815-21. doi: 10.1200/JCO.2009.24.2008. Epub 2009 Dec 21.

PMID:
20026800
36.

Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.

Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW, Brandwein J, Xu W, Mak DH, LaCasse E, Jacob C, Morris SJ, Jolivet J, Andreeff M.

J Clin Oncol. 2009 Oct 1;27(28):4741-6. doi: 10.1200/JCO.2009.21.8172. Epub 2009 Aug 3.

37.

Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma.

Chanan-Khan AA, Niesvizky R, Hohl RJ, Zimmerman TM, Christiansen NP, Schiller GJ, Callander N, Lister J, Oken M, Jagannath S.

Leuk Lymphoma. 2009 Apr;50(4):559-65. doi: 10.1080/10428190902748971.

PMID:
19373653
38.

The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.

Ringdén O, Pavletic SZ, Anasetti C, Barrett AJ, Wang T, Wang D, Antin JH, Di Bartolomeo P, Bolwell BJ, Bredeson C, Cairo MS, Gale RP, Gupta V, Hahn T, Hale GA, Halter J, Jagasia M, Litzow MR, Locatelli F, Marks DI, McCarthy PL, Cowan MJ, Petersdorf EW, Russell JA, Schiller GJ, Schouten H, Spellman S, Verdonck LF, Wingard JR, Horowitz MM, Arora M.

Blood. 2009 Mar 26;113(13):3110-8. doi: 10.1182/blood-2008-07-163212. Epub 2008 Dec 4.

39.

Acute myeloid leukemia in the elderly: conventional and novel treatment approaches.

Craig CM, Schiller GJ.

Blood Rev. 2008 Jul;22(4):221-34. doi: 10.1016/j.blre.2008.03.002. Epub 2008 Apr 22. Review.

PMID:
18433953
40.

Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.

Schiller GJ, Slack J, Hainsworth JD, Mason J, Saleh M, Rizzieri D, Douer D, List AF.

J Clin Oncol. 2006 Jun 1;24(16):2456-64. Epub 2006 May 1.

PMID:
16651647
41.

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.

Heidel F, Solem FK, Breitenbuecher F, Lipka DB, Kasper S, Thiede MH, Brandts C, Serve H, Roesel J, Giles F, Feldman E, Ehninger G, Schiller GJ, Nimer S, Stone RM, Wang Y, Kindler T, Cohen PS, Huber C, Fischer T.

Blood. 2006 Jan 1;107(1):293-300. Epub 2005 Sep 8.

42.

Myelodysplasic syndromes: a comprehensive review.

Catenacci DV, Schiller GJ.

Blood Rev. 2005 Nov;19(6):301-19. Review.

PMID:
15885860
43.
44.

The evolution of antibodies into versatile tumor-targeting agents.

Lin MZ, Teitell MA, Schiller GJ.

Clin Cancer Res. 2005 Jan 1;11(1):129-38. Review.

45.

Re: allogenic transplantation after nonmyelosuppressive conditioning--the effect of single-agent pentostatin.

Schiller GJ, Malone R, Figlin R.

Biol Blood Marrow Transplant. 2004 Aug;10(8):576-7. No abstract available.

PMID:
15328623
46.

Elimination of Aspergillus infection in allogeneic stem cell transplant recipients with long-term itraconazole prophylaxis: prevention is better than treatment.

Winston DJ, Emmanouilides C, Bartoni K, Schiller GJ, Paquette R, Territo MC.

Blood. 2004 Sep 1;104(5):1581; author reply 1582. No abstract available.

47.

Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of adult acute myelogenous leukemia in first complete remission.

Collisson EA, Lashkari A, Malone R, Paquette R, Emmanouilides C, Territo MC, Schiller GJ.

Leukemia. 2003 Nov;17(11):2183-8.

PMID:
12931210
48.

Myelodysplasia--therapeutic response to novel therapy and the need for new diagnostic groups.

Schiller GJ.

Leukemia. 2003 Jun;17(6):1183-5. Review. No abstract available.

PMID:
12764387
49.

Treatment of Scedosporium apiospermum brain abscesses with posaconazole.

Mellinghoff IK, Winston DJ, Mukwaya G, Schiller GJ.

Clin Infect Dis. 2002 Jun 15;34(12):1648-50. Epub 2002 May 16.

PMID:
12032903
50.

A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.

Winston DJ, Antin JH, Wolff SN, Bierer BE, Small T, Miller KB, Linker C, Kaizer H, Lazarus HM, Petersen FB, Cowan MJ, Ho WG, Wingard JR, Schiller GJ, Territo MC, Jiao J, Petrarca MA, Tonetta SA.

Bone Marrow Transplant. 2001 Jul;28(2):187-96.

Supplemental Content

Loading ...
Support Center